Summary by Moomoo AI
Aditxt, Inc., a biotech company, has responded to a comment from the U.S. Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-1, initially filed on January 25, 2024. The SEC's inquiry, dated February 12, 2024, pertained to Aditxt's proposed merger with Evofem Biosciences, Inc., and the acquisition of assets from MDNA Life Sciences, Inc., and Brain Scientific, Inc. Aditxt entered into a merger agreement with Evofem on December 11, 2023, which is pending approval from shareholders and the effectiveness of a registration statement on Form S-4. The SEC requested additional information on pro forma financial statements and financial statements of Evofem, as well as clarification on whether the acquisitions of MDNA and Brain Scientific assets required similar disclosures. Aditxt clarified...Show More